Patents Examined by Anish Gupta
  • Patent number: 7737109
    Abstract: A method of controlling obesity by physically narrowing the lumen of the pylorus One embodiment includes injection of a bio-compatible bulking or stiffening material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, narrowing the lumen, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be practiced or supplemented by cauterization of the pyloric sphincter or by suturing the sphincter to narrow the same and may be augmented by inducing flacid paralysis of the stomach by injecting botulinum toxin into the muscle tissue of the antrum or fundus of the stomach.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: June 15, 2010
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventor: Larry Sherwin Miller
  • Patent number: 7732412
    Abstract: The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: June 8, 2010
    Assignee: Zentaris GmbH
    Inventors: Michael Bernd, Bernhard Kutscher, Eckhard Gunther, Peter Romeis, Thomas Reissmann, Thomas Beckers
  • Patent number: 7728106
    Abstract: A method of making a synthetic glycopeptide, by addition of a synthetic oligosaccharide oxazoline to a GlcNAc-containing peptide precursor in the presence of an enzyme selected from among Endo-A and Endo-M. In a specific implementation, the method is utilized to synthesize a trivalent V3-domain glycopeptide including three V3-domain glycopeptides on a scaffold, wherein the three V3-domain glycopeptides are arranged to mimic the V3 domain presentation in trimeric gp120. Such trivalent V3-domain glycopeptides can be utilized in a vaccine for the treatment or prevention of HIV-1 infection.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: June 1, 2010
    Assignee: University of Maryland Biotechnology Institute
    Inventor: Lai-Xi Wang
  • Patent number: 7727960
    Abstract: The invention relates to a C5a receptor antagonist of structure (I), wherein X1 is a radical having a mass of about 1-300 and stands for R5-, R5-CO—, R5-N(R6)-CO—, R5-O—CO—, R5-SO2—, R5-N(R6)-SO2—, R5-N(R6)-, R5-N(R6)-CS—, R5-N(R6)-C(NH)—, R5-CS—, R5-P(O)OH—, R5-B(OH)— or R5-CH?N—O—CH2—CO—, wherein R5/R6 represent H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl or substituted aryloxyalkyl; X2=radical (biological bonding properties of a mimicrying phenylalanine unit); X3/X4=spacer (amino acids, amino-acid analogs and amino-acid derivatives); X5=radical (biological bonding properties of a mimicrying cyclohexylalanine or homoleucine unit); X6=radical (biological bonding properties of a mimicrying tryptophan unit); X7=radical (biological bonding properties of a mimicrying
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: June 1, 2010
    Assignee: Jerini AG
    Inventors: Gerd Hummel, Elsa Locardi, Thomas Polakowski, Dirk Scharn, Karsten Schnatbaum
  • Patent number: 7727963
    Abstract: The invention relates to synthetic tetrapeptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. An exemplary synthetic tetrapeptide amide of the invention is D-Phe-D-Phe-D-Leu-(?-Me) D-Lys-[4-Amidinohomopiperazine amide]: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 1, 2010
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Zhiyong Luo
  • Patent number: 7727719
    Abstract: The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: June 1, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: John K. Fink, Shirley Rainier
  • Patent number: 7727956
    Abstract: Nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases are described.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: June 1, 2010
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Franz Von Nussbaum, Nina Brunner, Rainer Endermann, Chantal Fuerstner, Elke Hartmann, Jacques Ragot, Guido Schiffer, Joachim Schuhmacher, Niels Svenstrup, Joachim Telser, Sonja Anlauf, Michael-Alexander Bruening
  • Patent number: 7727950
    Abstract: A kit of parts comprising two or more protein kinase substrate polypeptides, each said substrate polypeptide comprising a specificity conferring portion (which is different for each said kinase substrate polypeptide) and a phosphorylatable portion, wherein the phosphorylatable portions of each polypeptide are capable of being bound in a phosphorylation state-sensitive manner by the same specific binding partner, for example and antibody preparation, and wherein the said specific binding partner is not an antibody specific for phosphotyrosine, phosphoserine or phosphothreonine. The phosphorylatable portion preferably comprises the amino acid sequence LSFAEPG.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: June 1, 2010
    Assignee: The University of Dundee
    Inventors: Chris Armstrong, Philip Cohen
  • Patent number: 7723295
    Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: May 25, 2010
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Brian R. MacDonald, Jeffery Kenneth Weis, Edward John Yurkow
  • Patent number: 7723065
    Abstract: Organic compounds, such as precursors for aryl ethylamines such as ephedrine, aryl propylamines such as fluoxetine and propionic acid derivatives such as ibuprofen, naproxen and fenoprofen, are subjected to a yeast mediated reduction conducted in the absence of a solvent. The yeast is moistened with water and contacted with the organic compound. The yeast may then be contacted with an organic solvent to dissolve the product of the reaction into the solvent, and a solid/liquid separation used to separate the product from the yeast.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: May 25, 2010
    Assignee: Victoria University
    Inventors: Maurice Arthur Trewhella, Nick Athanasiou, Andrew John Smallridge
  • Patent number: 7723499
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: May 25, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Patent number: 7718620
    Abstract: The invention provides a method of treating or preventing ischemia-reperfusion injury of the kidney in a mammal. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: May 18, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Hazel H. Szeto, Kesheng Zhao, Peter W. Schiller
  • Patent number: 7718602
    Abstract: The utility of soybeans having a composition of greater than 40% of the protein as beta-conglycinin and less than 10% of the protein as glycinin for making highly functional high beta-conglycinin compositions was discovered. The discovered ingredients are useful for mimicking the texturizing properties of casein while also maintaining or improving physiological benefits of soy protein ingredients (e.g., cholesterol and triglyceride lowering properties). The high stability of the high beta-conglycinin compositions against protein-protein aggregation reactions is valuable for creating good tasting beverages and beverage mixes. Cheese with good spreadability, gloss and smoothness was made using an enzyme-modified version of the new ingredient composition. Cheese with good firmness and meltability was also created using a different enzyme-treatment High beta-conglycinin compositions were found to demonstrate excellent emulsifying and gelling properties in the pH region (5.5-6.2) relevant to meet applications.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: May 18, 2010
    Assignee: Monsanto Technology LLC
    Inventor: Neal A. Bringe
  • Patent number: 7718609
    Abstract: A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: May 18, 2010
    Assignee: Biodel Inc.
    Inventors: Solomon S. Steiner, Roderike Pohl
  • Patent number: 7718618
    Abstract: Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: May 18, 2010
    Assignees: The Regents of the University of California, National Jewish Medical and Research Center
    Inventors: Richard L. Gallo, Masamoto Murakami, Donald Y.M. Leung
  • Patent number: 7713937
    Abstract: The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 11, 2010
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
  • Patent number: 7713927
    Abstract: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: May 11, 2010
    Assignees: The Regents of the University of California, C3 Jian, Inc.
    Inventors: Jian He, Randal H. Eckert, Fengxia Qi, Maxwell H. Anderson, Wenyuan Shi
  • Patent number: 7713929
    Abstract: A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: May 11, 2010
    Assignee: Biodel Inc.
    Inventors: Solomon S. Steiner, Roderike Pohl
  • Patent number: 7709443
    Abstract: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: May 4, 2010
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Shouxin Liu, Wenxin Gu, Thomas E. Adrian, Gerald A. Soff
  • Patent number: 7709601
    Abstract: Combinatorially generated peptides are provided that have binding affinity for nylon (NY). The peptides may be used to deliver benefit agents to various NY surfaces.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: May 4, 2010
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Scott D. Cunningham, David J. Lowe, John P. O'Brien, Hong Wang, Antoinette E. Wilkins